Tag: Pharmstandard

Pharmstandard JSC, Russia’s leading pharmaceutical company, develops and manufactures modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients.
The most popular Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®. The Company manufactures more than 250 pharmaceutical products including drugs for treatments of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, contagious diseases, metabolic disorders, cancer and other diseases.

Rusatom Healthcare and MedInvestGroup set up a production of radiopharmaceuticals

Rusatom Healthcare JSC (integrator of Rosatom State Corporation radiation technologies) and MedInvestGroup LLC, a part of the Pharmstandard group, signed a cooperation agreement.

Gilead localizes the production of hepatitis C and HIV drugs in Russia

According to the agreement Pharmstandard production facilities will manufacture Sovaldi® for the treatment of chronic hepatitis C and Truvada® for the treatment of HIV.

Viriom intends to produce Elpida at the facilities of Pharmstandard

JSC Pharmstandard, a Russian pharmaceutical industry leader, and Viriom LLC, a company engaged in the development of innovative medicines, signed an agreement on intentions.

Pharmstandard will supply antiretroviral drug to Russian Ministry of Health

Pharmstandard turned out to be the only pharmaceutical company that made a bid for supplying rilpivirine + tenofovir + emtricitabine, a three-component antiretroviral medication included in the list of vital and essential drugs.

Janssen intends to manufacture bedaquiline at the Pharmstandard plant in Ufa

Janssen Pharmaceutica N.V., a part of Janssen Pharmaceutical Companies of Johnson & Johnson, signed a memorandum of intent with Pharmstandard JSC to manufacture and supply Sirturo®, a medicinal product.

Amgen will transfer technology for manufacturing of blinatumomab to Pharmstandard

Amgen and Pharmstandard announced the signing of an agreement on technology transfer, manufacturing and commercialization of blinatumomab in the Russian market

Bone Therapeutics and Cellthera Pharm intend to cooperate

Bone Therapeutics and Cellthera Pharm today announced the intention to collaborate in the field of cell-based therapies for orthopaedics and bone diseases

Takeda localizes the manufacturing of cancer drug at Pharmstandard-UfaVITA

UfaVita Factory
Takeda Pharmaceuticals LLC and Pharmstandard JSC announced the start of their cooperation to localize the manufacturing of brentuximab vedotin

Global players of pharmaceutical industry are interested in the Russian market

Sergey Tsyb
In October, the inter-agency commission will examine 3 projects of pharmaceutical companies that expressed a desire to conclude special investment contracts in the area of pharmaceutical industry.

Roche will localize the manufacturing of Gazyva at the facilities of Pharmstandard

Roche and Pharmstandard announced the signing of Supply and Manufacturing Contract and License Agreement aimed at providing the full-cycle localization of Gazyva

Innovative domestically produced cancer drugs are expected in the Russian market

In the future, new domestically produced drugs designed for the therapy of patients with oncological diseases will be available on the Russian market

Rostec, Pharmstandard and Kedrion established a joint venture

The National Immunobiological Company (part of Rostec State Corporation), Pharmstandard and Kedrion Biopharma (Italy) signed an agreement to establish Kirov Plasma, a joint-stock company. The company ...

Joint program on the plasma products manufacturing in the Russian Federation

The leading Russian pharmaceutical holding companies “National Immunobiological Company” (affiliated to the State Corporation Rostec) and PAO “Pharmstandart”, and Kedrion Biopharma, one of the major f...

GE Healthcare has announced the startup of the contrast medicines production

UfaVita Factory
This project will contribute to the development of the Russian pharmaceutical industry and also will meet the challenges of the state program “Pharma 2020”, oriented to increase the proportion of the essential medicines, manufactured in Russia.

Ferring localizes the production on Pharmstandart’s site

The global biopharmaceutical company Ferring Pharmaceuticals and the leading Russian pharmaceutical company OJSC “Pharmstandart” have announced the beginning of strategic partnership in the full cycle production of Traktocile (INN atosiban) and Pabal (INN carbetocin) used for the treatment of early labour and prevention of postpartum haemorrhage.